261.31MMarket Cap-1560P/E (TTM)
1.4600High1.3201Low2.21MVolume1.3500Open1.3600Pre Close3.11MTurnover1.35%Turnover RatioLossP/E (Static)184.02MShares1.928052wk High2.06P/B232.30MFloat Cap0.412652wk Low--Dividend TTM163.59MShs Float111.3600Historical High--Div YieldTTM10.29%Amplitude0.4126Historical Low1.4040Avg Price1Lot Size
Nektar Therapeutics Stock Forum
Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024
Nektar Therapeutics (Nasdaq: NKTR) unveiled preclinical data on NKTR-0165, a TNFR2 agonist antibody aimed at treating inflammatory diseases, at the EULAR 2024 Congress. NKTR-0165 is designed to selectively stimulate TNFR2 receptor activity, which is important for inflammation control and is associ...
• The company's TNFR2 agonist antibody, NKTR-0165, targets autoimmune diseases and is slated for clinical trials in the first half of 2025.
• Nektar ended the year with $329.4 million in cash and investments and expects 2024 revenues of $75...
MT Newswires· 1 min ago
Nektar Therapeutics (NKTR) said Monday that new preclinical data on NKTR-255 showed that a combination of the product candidate with obinutuzumab "significantly enhanced" the cytotoxicity of expanded Natural Killer or NK cells against rituximab-resistant Burkitt Lymphoma cells.
"Preclinical and early clinical data suggest that NKTR-255 can improve proliferation and pers...
No comment yet